Premature Ejaculation Treatment Market Enhancement in Medical Sector 2018 to 2026

Premature Ejaculation Treatment Market
Enhancement in Medical Sector 2018 to 2026
Premature Ejaculation Treatment Market by Drug Type (Selective
Serotonin Reuptake Inhibitors (SSRIs) (Dapoxetine, and Others),
Phosphodiesterase Type 5 (PDE5) Inhibitors (Zertane, and Others),
Topical Anesthetics, and Others), by Route of Administration (Oral and
Topical), by Dosage Form (Pills, Spray, and Others), by Distribution
Channel (Hospitals, Online Pharmacies, and Retail Pharmacies), and
Region (North America, Latin America, Europe, Asia Pacific, the Middle
East, and Africa) - Global Forecast to 2026
Premature ejaculation also called as rapid ejaculation, premature climax or early ejaculation. It is a
disorder, which causes early ejaculation of semen during sexual intercourse. Premature ejaculation is a
very common problem, and its exact cause is not known. However, causes include early sexual
experiences, sexual abuse, poor body image, depression, anxiety, abnormal hormone levels, inherited
traits, inflammation and infection of the prostate or urethra, and worrying about premature ejaculation.
The global Premature Ejaculation Treatment Market size was valued at US$ 1.5 Bn in 2017, and is
expected to witness a CAGR of 8.7% over the forecast period (2018 – 2026).
Market Dynamics
Increasing launches of novel products for the treatment of premature ejaculation is expected to fuel the
global premature ejaculation treatment market growth. For instance, in 2016, Regent Pacific Group
Limited, a Hong Kong-based investment group, launched its product, Fortacin in the U.K. Fortacin is a
topical spray, which contains low doses of two anesthetics - lidocaine and prilocaine and is indicated
for the treatment of premature ejaculation. Furthermore, increasing prevalence of premature ejaculation
due to unhealthy lifestyle and various factors such as depression and hormonal imbalance is expected
to rise demand for premature ejaculation treatment drugs. For instance, according to the data published
by National Center for BioDrug Type Information in 2016, around 25.8% of male in China are
suffering from premature ejaculation.
Frequent launches and approvals of novel premature ejaculation treatment products is expected
to drive growth of the market
Key players in the market are focusing on launching new products, which in turn is expected to aid in
growth of the market. For instance, in 2012, Absorption Pharmaceuticals, LLC launched its
Promescent, an over-the-counter lidocaine-based spray, indicated for premature ejaculation.
Furthermore, in 2013, Absorption Pharmaceuticals, LLC received patent for its Promescent, for
premature ejaculation (PE) from the U.S. Patent and Trademark Office. The launches of novel drugs,
which are indicated for the treatment of premature ejaculation is expected to fuel growth of the global
premature ejaculation treatment market in the near future.
Increasing strategic collaborations for development of new diagnostic tools is expected to propel
the market growth
Key players in the market are involved in strategic collaborations for the development of premature
ejaculation treatment drugs. For instance, in 2012, Ampio Pharmaceuticals, Inc. entered in a strategic
agreement with Ethypharm S.A. for the manufacturing of Zertane, Ampio's drug indicated for the
treatment of premature ejaculation. In 2013, Absorption Pharmaceuticals LLC entered into a strategic
collaboration with Kaiser Permanente for initiating clinical trial to evaluate the efficacy of Promescent
lidocaine spray for men with premature ejaculation (PE). Such strategic collaborations by key players
for the development, manufacturing, and evaluation of novel drugs is expected to fuel the global
premature ejaculation treatment market growth.
Competitive Landscape
Key players operating in the premature ejaculation treatment market include Regent Pacific Group
Limited, Menarini Group, Furiex Pharmaceuticals, Inc., Absorption Pharmaceuticals, LLC, Ampio
Pharmaceuticals, Inc., Aytu BioScience, NeuroHealing Pharmaceuticals Inc., and Dong-A
Pharmaceutical Co., Ltd.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/1956
Detailed Segmentation:
•Global Premature Ejaculation Treatment Market, By Drug Type :
•Selective Serotonin Reuptake Inhibitors (SSRIs)
•Dapoxetine
•Others
•Phosphodiesterase Type 5 (PDE5) Inhibitors
•Zertane
•Others
•Topical Anesthetics
•Others
•Global Premature Ejaculation Treatment Market, By Route of Administration:
•Oral
•Topical
•Global Premature Ejaculation Treatment Market, By Dosage Form:
•Pills
•Spray
•Others
•Global Premature Ejaculation Treatment Market, By Distribution Channel:
•Hospitals
•Online Pharmacies
•Retail Pharmacies
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]

Premature ejaculation also called as rapid ejaculation, premature climax or early ejaculation. It is a disorder, which causes early ejaculation of semen during sexual intercourse. Premature ejaculation is a very common problem, and its exact cause is not known. However, causes include early sexual experiences, sexual abuse, poor body image, depression, anxiety, abnormal hormone levels, inherited traits, inflammation and infection of the prostate or urethra, and worrying about premature ejaculation. The global Premature Ejaculation Treatment Market size was valued at US$ 1.5 Bn in 2017, and is expected to witness a CAGR of 8.7% over the forecast period (2018 – 2026).

Download Report